• Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, and Huawei Jin.
• Affiliated Hospital of Shaoxing University of Edocrine and Metabolism Department, Zhejiang, China.
• Medicine (Baltimore). 2021 Feb 19; 100 (7): e24873e24873.

BackgroundGlucokinase activators are a novel family of glucose-lowering agents used for the treatment of type-2 diabetes mellitus (T2DM). Glucokinase activators blind to GK activate the enzyme allosterically. Treatment with different GKAs has been shown to reduce fasting and postprandial glucose in patients with type 2 diabetes. We compared the efficacy/safety of glucokinase activators in T2DM patients through a meta-analysis.MethodsWe searched PubMed, Excerpt Medica Database, and Cochrane Central Register of Controlled Trials databases for articles published before December 30, 2020. Two independent reviewers extracted the information from article. The quality of articles were assessed by 2 independent reviewers using the 5 items of scale proposed by Jadad. We computed the weighted mean difference and 95% confidence interval (CI) for a change from baseline to the study endpoint for glucokinase activators vs placebo. Egger test and Begg test were used to assess the possible publication bias caused by the tendency of published studies to be positive.ResultsThe present meta-analysis will compare the efficacy and safety of glucokinase activators and placebo for the treatment of T2DM.ConclusionsThis meta-analysis will provide advanced evidence on the efficacy and safety of glucokinase activators for the treatment of T2DM.Ethics And DisseminationEthical approval and patient consent are not required because this study is a literature-based study. This systematic review and meta-analysis will be published in a peer-reviewed journal.Prospero Registration NumberCRD42021220364.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

35 keywords...

hide…